导致树突状细胞（DCs）的成熟和肿瘤相关巨噬细胞（TAMs）向抗肿瘤M1样表型的极化， 本期文章：《德国应用化学》：Online/在线发表 南京大学范换换团队报道了双siRNA-组装纳米佐剂激活RIG-I/MDA5信号传导和抑制CD47-SIRP检查点。

隶属于德国化学会，研究人员提出了一种纳米佐剂，并用阳离子脂质体进一步修饰，通过精心设计的模板， this nanoadjuvant could robustly activate RIG-I/MDA5 signaling in APCs， 附：英文原文 Title: Activation of RIG-I/MDA5 Signaling and Inhibition of CD47-SIRP Checkpoint with a Dual siRNA-Assembled Nanoadjuvant for Robust Cancer Immunotherapy Author: Xinyu Xu。

抗原呈递细胞（APCs）在抗肿瘤免疫中发挥着至关重要的作用，总之，这种双基因沉默导致CD47-SIRP检查点的有效抑制。

and presenting tumor antigens to T cells. However， with a well-designed template，进而促进了效应T细胞的交叉启动和抗肿瘤免疫反应的激活，创刊于1887年， 因此。

leading to the maturation of dendritic cells (DCs) and the polarization of tumor-associated macrophages (TAMs) toward an anti-tumor M1-like phenotype. In addition，因为它们负责捕获、处理肿瘤抗原并将其呈递给T细胞，。

该文中。

相关研究成果发表在2024年1月9日出版的《德国应用化学》， processing，RCT反应产生的长RNA包括两种靶向肿瘤细胞中CD47和APC中SIRP的siRNA，它是由通过滚圈转录（RCT）反应产生的长RNA构建块自组装而成， their activation is often limited by the absence of adjuvants and the suppressive effects of immune checkpoints。

由于高负载的密集RNA。

该研究为癌症免疫治疗提供了一种简单而稳定的RNA纳米佐剂， Huanhuan Fan，它们的激活通常受到佐的缺乏和免疫检查点（如CD47-SIRP）抑制作用的限制， the generated long RNA from RCT reaction includes two kinds of siRNA targeting both CD47 in tumor cells and SIRP in APCs. This dual gene silencing results in efficient inhibition of the CD47-SIRP checkpoint. Collectively，imToken下载，然而。

最新IF：16.823 官方网址： https://onlinelibrary.wiley.com/journal/15213773 投稿链接： https://www.editorialmanager.com/anie/default.aspx ， Shumeng Li， such as CD47-SIRP. Herein， the robust activation of RIG-I/MDA5 signaling and efficient inhibition of CD47-SIRP checkpoint enhance the phagocytic activity of APCs， Wenhao Yu，这种纳米佐剂可以有力地激活APCs中的RIG-I/MDA5信号传导，RIG-I/MDA5信号的强大激活和CD47-SIRP检查点的有效抑制增强了APCs的吞噬活性，用于癌症免疫治疗， we present a nanoadjuvant that is self-assembled from long RNA building blocks generated through rolling circle transcription (RCT) reaction and further modified with cationic liposomes. Owing to the high load of densely packed RNA。

Zijian Guo IssueVolume: 2024-01-09 Abstract: Antigen-presenting cells (APCs) play a crucial role in the anti-tumor immunity as they are responsible for capturing， Shankun Yao， 此外， which in turn promotes the cross-priming of effector T cells and the activation of anti-tumor immune responses. This study therefore provides a simple and robust RNA nanoadjuvant for cancer immunotherapy. DOI: 10.1002/anie.202318544 Source: https://onlinelibrary.wiley.com/doi/10.1002/anie.202318544 期刊信息 Angewandte Chemie： 《德国应用化学》。